WhaleCreep

Avidity Partners Management LP 13F holdings, Q4 2021

Hedge fundSEC filingsCompare with another fundHoldings as of 2021-12-31, filed 2022-02-14

Avidity Partners Management LP disclosed 97 US equity positions worth $4.7bn in its Q4 2021 13F filing. Its largest position is ABBV at 5.7% of the reported book, followed by ZNTL and ARVN. Versus Q3 2021 it opened 16 new positions, added to 41, reduced 15 and exited 22.

$4.7bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
97
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
5.7%
Largest position
The largest single position as a share of the reported equity book.
37.6%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
41
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2021: 16 new, 41 added, 15 reduced, 22 exited

50 of 97
ABBV ABBVIE INCHealthcare5.7%$269m1.99m+23%added
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare4.8%$228m2.71m+8.9%added
ARVN ARVINAS INCHealthcare4.4%$208m2.53m+13%added
AVTR AVANTOR INCHealthcare4.3%$202m4.79m+48%added
AZN ASTRAZENECA PLCHealthcare3.5%$167m2.87m+103%added
BIOHAVEN PHARMACTL HLDG CO L no ticker–3.3%$157m1.14m+22%added
BAX BAXTER INTL INCHealthcare3.2%$152m1.76m+105%added
ELV ELEVANCE HEALTH INCHealthcare3.2%$149m321,000–new
PFE PFIZER INCHealthcare2.6%$123m2.09m+104%added
MRTXEUR MIRATI THERAPEUTICS INC–2.5%$118m806,400−24%reduced
OPHTEUR IVERIC BIO INC–2.5%$116m6.96m+70%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare2.5%$116m535,000+52%added
ARNAEUR ARENA PHARMACEUTICALS INC–2.4%$113m1.22m+6.7%added
HORIZON THERAPEUTICS PUB L no ticker–2.3%$109m1.01m+23%added
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.3%$107m1.26m+48%added
2655787D BLUEPRINT MEDICINES CORP–2.3%$107m995,000+20%added
SGENUSD SEAGEN INC–2.2%$106m685,000+28%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.2%$106m4.82m0.0%held
LLY ELI LILLY & COHealthcare2.0%$95.2m344,800+4.5%added
CTLTEUR CATALENT INC–1.9%$89.0m695,000+75%added
NTRA NATERA INCHealthcare1.9%$87.8m940,000+47%added
HO1 HOLOGIC INC–1.7%$81.5m1.06m+13%added
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare1.5%$72.2m3.78m+159%added
SHC SOTERA HEALTH COHealthcare1.5%$69.7m2.96m+24%added
NUVB NUVATION BIO INCHealthcare1.3%$62.8m7.38m+1.6%added
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare1.3%$62.7m370,000−13%reduced
UNH UNITEDHEALTH GROUP INCHealthcare1.3%$61.8m123,100–new
VRTX VERTEX PHARMACEUTICALS INCHealthcare1.3%$61.5m280,000−70%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare1.3%$60.4m2.55m+4.8%added
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.2%$58.9m700,000+54%added
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.2%$58.0m875,000+30%added
STVN STEVANATO GROUP S P AHealthcare1.2%$57.1m2.54m0.0%held
2JQ GRITSTONE BIO INC–1.2%$56.2m4.37m−2.0%reduced
KEZAR LIFE SCIENCES INC no ticker–1.1%$54.0m3.23m+1142%added
ACET ADICET BIO INCHealthcare1.1%$53.1m3.03m+25%added
RNAGBP AVIDITY BIOSCIENCES INC–0.9%$43.1m1.81m+10%added
KYMR KYMERA THERAPEUTICS INCHealthcare0.9%$42.5m670,000+30%added
IMCR IMMUNOCORE HLDGS PLCHealthcare0.9%$42.1m1.23m+12%added
CRBU CARIBOU BIOSCIENCES INCHealthcare0.9%$40.4m2.67m+8.1%added
INSM INSMED INCHealthcare0.8%$39.5m1.45m+12%added
ORTHO CLINICAL DIAGNOSTICS H no ticker–0.8%$38.3m1.79m−25%reduced
PHAT PHATHOM PHARMACEUTICALS INCHealthcare0.8%$37.3m1.90m–new
EPIEUR ESSA PHARMA INC–0.7%$34.9m2.46m+0.4%held
AMN AMN HEALTHCARE SERVICES INCHealthcare0.7%$34.3m280,100–new
LEGN LEGEND BIOTECH CORPHealthcare0.7%$33.2m711,900−20%reduced
ATEC ALPHATEC HLDGS INCHealthcare0.7%$31.7m2.77m−0.5%held
BLU BELLUS HEALTH INC NEW–0.6%$30.4m3.77m−24%reduced
VIR VIR BIOTECHNOLOGY INCHealthcare0.6%$29.3m700,000+36%added
AXSM AXSOME THERAPEUTICS INC.Healthcare0.6%$29.3m775,000–new
SPNEUSD SEASPINE HLDGS CORP–0.6%$27.4m2.01m+3.4%added

Exited since Q3 2021

22 rows
REGN REGENERON PHARMACEUTICALS2.3%$92.2m
EXK EXACT SCIENCES CORP0.9%$35.2m
CMPS COMPASS PATHWAYS PLC0.9%$34.7m
NTLA INTELLIA THERAPEUTICS INC0.9%$33.7m
NBP NOVABRIDGE BIOSCIENCES0.8%$32.9m
SANA SANA BIOTECHNOLOGY INC0.4%$17.4m
PATH UIPATH INC0.4%$16.8m
LFST LIFESTANCE HEALTH GROUP INC0.4%$14.5m
GHRS GH RESEARCH PLC0.3%$12.4m
ACIU AC IMMUNE SA0.3%$11.7m
HARPOON THERAPEUTICS INC no ticker0.2%$9.4m
ESMTUSD ENGAGESMART INC0.2%$9.4m
ORTXUSD ORCHARD THERAPEUTICS PLC0.2%$8.8m
ZETA ZETA GLOBAL HOLDINGS CORP0.2%$7.6m
XLRN ACCELERON PHARMA INC0.2%$6.0m
KROS KEROS THERAPEUTICS INC0.1%$5.7m
HEALTHCOR CATALIO ACQU CORP no ticker0.1%$5.0m
LIFESCI ACQUISITION II CORP no ticker0.10%$3.9m
ZLAB ZAI LAB LTD0.10%$3.8m
NAUT NAUTILUS BIOTECHNOLOGY INC0.09%$3.7m
SGHT SIGHT SCIENCES INC0.08%$3.3m
ATAI BECKLEY NV no ticker0.08%$3.2m

Sector mix

  • Healthcare68.0%
  • Unclassified31.8%
  • Technology0.2%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters